Clinical trials: Oral Phase
Advanced Solid Tumor, Metastatic Breast Cancer
ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
This study evaluates the anti-tumor effects of ORIN 1001 in patients with advanced solid tumors or relapsed refractory metastatic breast cancer (patients with progressive disease after receiving at least two lines of therapy in…
- Trial name
- NCT03950570
- Testing
- Abraxane, ORIN1001
- Where
- 20 sites in United States
- Volunteers
- 58 people
- Sponsor
- Orinove, Inc.
Mantle-Cell Lymphoma
Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma
The purposes of this study are to determine the safety of oral enzastaurin and any side effects that might be associated with it and whether enzastaurin can help participants with mantle cell lymphoma.
- Trial name
- NCT00088205
- Testing
- enzastaurin
- Where
- 17 sites in Australia, France and 2 more
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Phenylketonuria
Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of CDX-6114 in Patients With Phenylketonuria (PKU)
This study is an international, multi-center, randomized, double-blind, placebo-controlled, two-treatment, two-period cross-over study to evaluate the pharmacodynamics, safety, tolerability and pharmacokinetics of a single oral…
- Trial name
- NCT04085666
- Testing
- CDX 6114
- Where
- 2 sites in Australia, Germany
- Volunteers
- 18 people
- Sponsor
- Société des Produits Nestlé (SPN)
Healthy
Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 After Single and Multiple Ascending Oral Doses in Healthy Young and Elderly Japanese Subjects
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of AZD5213 in healthy young and elderly Japanese subjects
- Trial name
- NCT01335451
- Testing
- AZD5213
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
EGFR Positive Non-small Cell Lung Cancer, Non Small Cell Lung Cancer
Osimertinib for Advanced EGFR-positive NSCLC Patients
Lung cancer is the leading cause of cancer incidence (11.6%) and mortality (18.4%) globally[1]. Development of targeted therapies in the context of precision medicine changed the way lung cancer was diagnosed and treated.
- Trial name
- NCT05037331
- Where
- Singapore
- Volunteers
- 58 people
- Sponsor
- National University Hospital, Singapore
Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Infigratinib is an oral drug which selectively binds to fibroblast growth factor receptor (FGFR) 2 and is being developed to treat participants with FGFR2 mutated cholangiocarcinoma.
- Trial name
- NCT03773302
- Testing
- BGJ398, Gemcitabine, Cisplatin
- Where
- 116 sites in United States, Australia and 13 more
- Volunteers
- 48 people
- Sponsor
- QED Therapeutics, a BridgeBio company
Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer
Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin for Advanced Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00003580
- Testing
- amifostine trihydrate, cisplatin, radiation therapy
- Where
- United States
- Sponsor
- University of Tennessee
Carcinoma, Carcinoma, Non-Small-Cell Lung
Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer
The purpose of this study is to determine the maximum safe dose of orally administered Karenitecin (BNP1350) in patients with solid tumors.
- Trial name
- NCT00097903
- Testing
- Karenitecin (BNP1350)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- BioNumerik Pharmaceuticals, Inc.
Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer
BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer
This phase I trial will determine the Maximum Tolerated Dose (MTD) of BKM120 when given together with fulvestrant in treating postmenopausal patients with estrogen receptor-positive (ER+) stage IV breast cancer.
- Conditions
- Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT01339442
- Testing
- BKM120, Fulvestrant, biopsy
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Washington University School of Medicine
Asthma
A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma
This study will compare efficacy and safety of different regimens of olodaterol administration in asthma (once daily, twice daily) with placebo in a complete cross-over design each within one of the two daily dose groups (medium…
- Trial name
- NCT01311661
- Testing
- Olodaterol low daily dose twice daily, Olodaterol medium daily dose twice daily
- Where
- 36 sites in United States, Austria and 4 more
- Volunteers
- 206 people
- Sponsor
- Boehringer Ingelheim
Disintegration, Healthy
Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms
This study is to find out how different types of capsules or tablets containing EDP1815 move through the GI tract and release the drug after being swallowed.
- Trial name
- NCT05066373
- Testing
- EDP1815 capsule A, EDP1815 capsule B, EDP1815 tablet
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Evelo Biosciences, Inc.
Carcinoma, Non-Small-Cell Lung, Chemotherapy, Adjuvant
Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC
In this study, a pragmatic, open labelled, multi-center randomized controlled trial will be conducted. The study population are stage II and IIIA NSCLC patients undergoing R0 resection and will be scheduled for adjuvant…
- Trial name
- NCT03712969
- Testing
- Shenlingcao Oral Liquid
- Where
- China
- Volunteers
- 527 people
- Sponsor
- West China Hospital
HIV Infections, Pregnancy
Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women
The purpose of this study is to examine the drug interactions between a protease inhibitor (PI)-based regimen including lopinavir/ritonavir (LPV/r) and two forms of contraceptive medications in HIV infected women.
- Trial name
- NCT00125983
- Testing
- Lopinavir/ritonavir, Ortho Novum 1/35, Ortho Evra
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 32 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pain
Omnitram Pharmacokinetic Study In Healthy Volunteers
The purpose of this study is to compare the safety, pharmacokinetic properties (the absorption, distribution and excretion), and analgesic activity of Omnitram (10 mg tablets), Tramadol (Ultram, 50 mg tablet) following oral…
- Trial name
- NCT02205554
- Testing
- Omnitram, Tramadol
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Syntrix Biosystems, Inc.
Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
For patients with leukemia who have not responded to or have progressed after an initial response to standard therapy, therapeutic options are limited.
- Conditions
- Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Myeloproliferative Disease, Chronic Myeloid Leukemia
- Trial name
- NCT01167166
- Testing
- rigosertib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Traws Pharma, Inc.
Alcohol Abuse, Alcohol Abuse/addiction
A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder
This study will evaluate the safety and exploratory efficacy of AFA-281 in patients with Alcohol use disorder on cravings, subjective response to alcohol, pain thresholds, anxiety, depression, and sleep.
- Conditions
- Alcohol Abuse, Alcohol Abuse/addiction, Anxiety, Pain Threshold
- Trial name
- NCT06710431
- Testing
- AFA-281
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Afasci Inc
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
- Trial name
- NCT03893682
- Testing
- CG-806
- Where
- 30 sites in United States
- Volunteers
- 36 people
- Sponsor
- Aptose Biosciences Inc.
Healthy Subjects
First-into-human Study of NS-136 in Healthy Subjects
The goal of this clinical trial is to exlplore the profile of NS-136 in health conditions. The main questions it aims to answer are: Is NS-136 safe and tolerable in heathy subjects under tested dosing regimen? What is the…
- Trial name
- NCT06345703
- Testing
- NS-136 tablet
- Where
- 2 sites in Australia, China
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- NeuShen Therapeutics
Renal Cell Carcinoma, Melanoma
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
The purpose of this study is to compare the effects of Infliximab and oral prednisone versus methylprednisolone and oral prednisone in patients with melanoma, lung cancer, or renal cell carcinoma who have immune related Grade 3-4…
- Conditions
- Renal Cell Carcinoma, Melanoma, Lung Cancer
- Trial name
- NCT02763761
- Testing
- Infliximab + Prednisone, Methylprednisolone + Prednisone
- Where
- 10 sites in United States
- Sponsor
- Bristol-Myers Squibb
Pneumonia, Pneumocystis Carinii, HIV Infections
A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Children Who Cannot Take Trimethoprim-Sulfamethoxazole
Primary: To compare the pharmacokinetics of biweekly and monthly dose regimens of intravenous pentamidine in HIV-infected infants and children who require PCP prophylaxis and who are intolerant to oral trimethoprim …
- Trial name
- NCT00001027
- Testing
- Pentamidine isethionate
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 32 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.